Avenue Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidate, intravenous tramadol (IV tramadol) is a novel therapy in development in the United States for managing post-operative pain as an alternative to conventional narcotics. The drug is designed to use a dual mechanism of action to block a patientâ€™s pain signal with reduced abuse potential. This unique mechanism of action includes an opioid agonist and an inhibitor of norepinephrine and serotonin re-uptake.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
10/09/26	US$0.8240	+26.42%	37,513
09/09/26	US$0.6518	+20.70%	7,408
08/09/26	US$0.5400	-0.82%	5,756
04/09/26	US$0.5445	-4.48%	4,000
02/09/26	US$0.5700	+9.62%	10,256

Delayed Quote OTC Markets

More quotes

Annual profits - Rate of surprise

Company calendar

Market Closed - OTC Markets 19:37:32 10/09/2026 BST			5-day change	1st Jan Change
0.8240 ^USD	+26.42%		+44.56%	+21.14%

08-07	Avenue Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-08	Avenue Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	2.15M 1.85M 1.74M 1.59M 2.97M 205M 2.99M 20.75M 7.99M 104M 8.06M 7.89M 331M	P/E 2024	-0.22x	P/E 2025	-0.73x
Enterprise Value	-707K -608K -574K -523K -977K -67.63M -986K -6.84M -2.63M -34.3M -2.66M -2.6M -109M	EV / Sales 2024	-	EV / Sales 2025	-491,128x
Free-Float	86.49%	Yield 2024 *	-	Yield 2025	-

08-07	Avenue Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-08	Avenue Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-30	Avenue Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-29	Avenue Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
02-23	Avenue Therapeutics, Inc. Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease	CI
11-13	Avenue Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-11	Axsome Therapeutics, Inc. completed the acquisition of Baergic Bio, Inc. from Avenue Therapeutics, Inc..	CI
11-06	Axsome Therapeutics acquires AZD7325, a selective GABA-A modulator for treatment of epilepsy	RE
11-05	Axsome Therapeutics, Inc. entered into stock purchase agreement to acquire Baergic Bio, Inc. from Avenue Therapeutics, Inc. for $83.3 million.	CI
14/08/25	Avenue Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
15/05/25	Avenue Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
30/04/25	Avenue Therapeutics, Inc. and Annji Pharmaceutical Co., Ltd. Enters into A License Termination	CI
31/03/25	Avenue Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI

02-23	Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease	AQ
11-06	Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics	AQ
14/11/24	Avenue Therapeutics : Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights Form 8 K	PU
14/11/24	Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights	AQ
09/10/24	Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit	AQ

Avenue Therapeutics, Inc. Share Price

Stocks

ATXI

US05360L4032

Biotechnology & Medical Research

Valuation : Avenue Therapeutics, Inc.

Chart: Avenue Therapeutics, Inc.

Latest news : Avenue Therapeutics, Inc.

Analysts' recommendations : Avenue Therapeutics, Inc.

Press Releases : Avenue Therapeutics, Inc.

News in other languages : Avenue Therapeutics, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : Avenue Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

18/04/23	MÄRKTE USA/Anleger bleiben in Deckung und warten Quartalszahlen ab
18/04/23	MÄRKTE USA/Anleger mit Blick auf Berichtssaison zurückhaltend
18/04/23	MÄRKTE USA/Uneinheitlich - Goldman Sachs bremst Dow
18/04/23	MÄRKTE USA/Wall Street dürfte Schwung des späten Vortageshandels halten
09/03/23	Wall Street hard onderuit in aanloop naar banencijfer

1 day	+26.42%
1 week	+44.56%
Current month	+82.30%
1 month	+223.01%
3 months	+128.89%
6 months	+205.19%
Current year	+21.14%

1 week	0.49	0.85
1 month	0.26	0.85
Current year	0.15	0.85
1 year	0.15	0.97
3 years	0.15	64.27
5 years	0.15	2,081.25
10 years	0.15	13,882.3

Manager	Title	Age	Since
Alexandra MacLean CEO	Chief Executive Officer	59	31/07/2022
David Jin CEO	Chief Executive Officer	36	30/03/2022
Jaclyn Jaffe IRC	Investor Relations Contact	-	-

Director	Title	Age	Since
Lindsay Rosenwald CHM	Chairman	71	08/02/2015
Neil Herskowitz BRD	Director/Board Member	69	31/07/2015
Jay Kranzler CHM	Chairman	68	06/03/2023

Date	Insider	Type	Main position	Quantity	% Market Cap.
02/01/26	FORTRESS BIOTECH, INC.	Free	Company	111,209	3.4934%
31/03/25	FORTRESS BIOTECH, INC.	Free	Company	33,724	1.6419%
31/12/24	FORTRESS BIOTECH, INC.	Other	Company	294,800	15.4214%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AVENUE THERAPEUTICS, INC.	+26.42%	+44.56%	-7.31%	-98.54%	2.15M
WUXI APPTEC CO., LTD.	-0.25%	-0.96%	+45.25%	+102.76%	68.52B
ARGENX SE	-1.09%	-4.97%	+31.10%	+76.56%	62.88B
INSMED INCORPORATED	-1.18%	+0.51%	-13.53%	+384.69%	28.13B
WUXI BIOLOGICS (CAYMAN) INC.	-2.74%	-3.53%	+26.13%	+13.50%	25.56B
BIONTECH SE	-1.76%	-7.14%	-5.57%	-19.75%	24.65B
GENMAB A/S	-2.39%	-4.23%	+18.42%	-20.95%	19.81B
PHARMAESSENTIA CORPORATION	-1.86%	+1.15%	+205.44%	+353.89%	17.69B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.37%	-3.77%	-9.38%	+528.34%	14.66B
EXELIXIS, INC.	-1.54%	-1.88%	+50.03%	+159.75%	14.45B
Average	+1.22%	+0.24%	+34.06%	+148.03%	27.64B
Weighted average by Cap.	-1.28%	-1.41%	+35.43%	+139.07%

	2024	2025
Net sales	-	1.4 1.21 1.14 1.04 1.94 134.23 1.96 13.57 5.22 68.09 5.27 5.16 216.26
Net income	-11.65M -10.02M -9.45M -8.61M -16.1M -1.11B -16.25M -113M -43.34M -565M -43.76M -42.8M -1.79B	-2.91M -2.5M -2.36M -2.15M -4.02M -278M -4.06M -28.11M -10.82M -141M -10.92M -10.69M -448M
Net Debt	-2.59M -2.23M -2.1M -1.92M -3.58M -248M -3.62M -25.07M -9.65M -126M -9.74M -9.53M -400M	-2.86M -2.46M -2.32M -2.11M -3.95M -273M -3.98M -27.59M -10.62M -138M -10.72M -10.49M -440M